Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven solid tumor for which gemcitabine is a treatment option or for which no effective therapy exists
• Previously untreated disease allowed
• No large and potentially symptomatic pericardial effusion or undrained pleural effusion (with or without pleurodesis)
• No CNS metastases
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Life expectancy:
• At least 12 weeks
• Hematopoietic:
• Absolute neutrophil count at least 2,000/mm3
• Platelet count at least 100,000/mm3
• No prior thrombotic events
• Hepatic:
• Bilirubin no greater than 1.5 mg/dL
• SGOT no greater than 2 times upper limit of normal
• Renal:
• Creatinine no greater than 1.5 mg/dL
• Cardiovascular:
• No clinically significant cardiac disease
• No prior deep venous thrombus
• No prior arterial vascular event
• No prior myocardial infarction
• No unstable angina
• No prior transient ischemic attack or cerebrovascular accident
• No cardiac arrhythmias that could be related to cardiac ischemia
• Pulmonary:
• No clinically significant pulmonary disease
• No history of pulmonary embolism
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active infection
• No severe malnutrition or intractable emesis
• No chronic diarrheal disease within the past 6 months
• PRIOR CONCURRENT THERAPY:
• Chemotherapy:
• No more than 1 prior chemotherapy regimen
• At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• Prior gemcitabine or flavopiridol allowed
• No other concurrent chemotherapy
• Radiotherapy:
• At least 3 weeks since prior radiotherapy and recovered
• No prior radiotherapy to more than 50% of bone marrow
• No concurrent radiotherapy